eFFECTOR Therapeutics announces the initiation of an investigator-sponsored trial in collaboration with the Dana-Farber Cancer Institute

eFFECTOR Therapeutics shared a post on LinkedIn:

“We are excited to announce the initiation of an investigator-sponsored trial evaluating our lead product candidate in patients with estrogen receptor-positive (ER+) endometrial cancer ovarian cancer, in collaboration with the Dana-Farber Cancer Institute. ”

Source: eFFECTOR Therapeutics/LinkedIn